Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy
By Adria Calatayud
Novartis and Medicines for Malaria Venture said a new treatment for babies with malaria who weigh less than 5 kilograms showed positive efficacy and safety effects in a clinical study.
Swiss pharmaceutical company Novartis and nonprofit organization Medicines for Malaria Venture said Wednesday that they submitted data from their phase 2 and 3 trial for regulatory review.
The study analyzed a new formulation of Novartis's Coartem drug to account for metabolic differences in the smallest babies, they said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 24, 2024 01:31 ET (05:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations